Ultibro Breezhaler Inhalation (Dry Powder)
Indacaterol + Glycopyrronium
"0.05 mg, 0.110mg"
Novartis Pharma AG
| Pack size | 30's (6's Blister x 5) + 1 Inhaler |
|---|---|
| Dispensing mode | POM |
| Source | SWITZERLAND |
| Agent | CITY MEDICAL STORE |
| Retail Price | 297.50 AED |
Indications
Ultibro Breezhaler Inhalation (Dry Powder) is used for:
Bronchodilator treatment to relieve symptoms in patients with, chronic obstructive pulmonary disease (COPD).
Adult Dose
Adult
Chronic Obstructive Pulmonary Disease (COPD)
Inhale 1 cap with inhaler once daily.
Hepatic Impairment: This can be used at the recommended dose in patients with mild and moderate hepatic impairment. There are no data available for the use of Indacaterol + Glycopyrronium Breezhaler in patients with severe hepatic impairment, therefore caution should be observed in these patients.
Child Dose
Safety and efficacy not established
Renal Dose
Renal Impairment: This can be used at the recommended dose in patients with mild to moderate renal impairment. In patients with severe renal impairment or end-stage renal disease requiring dialysis it should be used only if the expected benefit outweighs the potential risk.
Administration
For inhalation use only. The capsules must not be swallowed.
Contra Indications
Hypersensitivity to indacaterol, glycopyrronium or to any of the excipients of Indacaterol + Glycopyrronium. All LABAs are contraindicated in patients with asthma without use of a long-term asthma control medication Indacaterol/glycopyrrolate is not indicated for the treatment of asthma
Use in children: This should not be used in patients <18 years.
Precautions
Concomitant use w/ long-acting beta-agonists or long-acting muscarinic antagonists. Not for the treatment of asthma. Immediately discontinue use if hypersensitivity & paradoxical bronchospasm occurs. Narrow-angle glaucoma, urinary retention, CV disorders (CAD, acute MI, cardiac arrhythmia, HTN), convulsive disorders or thyrotoxicosis, severe renal impairment; hypokalaemia; hyperglycaemia. Pregnancy & lactation.
Pregnancy-Lactation
Pregnancy
There are no adequate and well-controlled studies in humans with Utibron Neohaler or its individual components
Animal studies have not shown teratogenicity
Lactation
Unknown if distributed in human breast milk
Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition
Interactions
Decreases levodopa effects. Effects may be enhanced by using drugs with antimuscarinic properties or MAOIs concurrently. May antagonise the GI effects of cisapride, metoclopramide and dompeidone.
Potentially Fatal: IV admin in the presence of cyclopropane anesth can result in ventricular arrhythmias.
Adverse Effects
Side effects of Indacaterol + Glycopyrronium :
1-10%
Nasopharyngitis (4.1%), Hypertension (2%), Back pain (1.8%), Oropharyngeal pain (1.6%)
Mechanism of Action
Glycopyrronium: Long-acting muscarinic antagonist (LAMA); often referred to as an anticholinergic; produces bronchodilation by inhibiting acetylcholine’s effect on muscarinic receptors in the airway smooth muscle
Indacaterol: Long-acting beta2-agonist (LABA); stimulates intracellular adenyl cyclase, causing conversion of ATP to cyclic AMP; increased cyclic AMP levels cause relaxation of bronchial smooth muscle
Note
Ultibro Breezhaler "0.05 mg, 0.110mg" Inhalation (Dry Powder) manufactured by Novartis Pharma AG. Its generic name is Indacaterol + Glycopyrronium. Ultibro Breezhaler is availble in United Arab Emirates.
Farmaco UAE drug index information on Ultibro Breezhaler Inhalation (Dry Powder) is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.